FI3261679T3 - Geeniterapia näön parantamiseen - Google Patents

Geeniterapia näön parantamiseen Download PDF

Info

Publication number
FI3261679T3
FI3261679T3 FIEP16706413.8T FI16706413T FI3261679T3 FI 3261679 T3 FI3261679 T3 FI 3261679T3 FI 16706413 T FI16706413 T FI 16706413T FI 3261679 T3 FI3261679 T3 FI 3261679T3
Authority
FI
Finland
Prior art keywords
use according
aav vector
pin
photoreceptor
macular degeneration
Prior art date
Application number
FIEP16706413.8T
Other languages
English (en)
Finnish (fi)
Inventor
Matteo Rizzi
Robin Ali
Alexander Smith
Koji Nishiguchi
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Application granted granted Critical
Publication of FI3261679T3 publication Critical patent/FI3261679T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP16706413.8T 2015-02-23 2016-02-19 Geeniterapia näön parantamiseen FI3261679T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201503008A GB201503008D0 (en) 2015-02-23 2015-02-23 Treatment
PCT/GB2016/050419 WO2016135457A1 (en) 2015-02-23 2016-02-19 Gene therapy to improve vision

Publications (1)

Publication Number Publication Date
FI3261679T3 true FI3261679T3 (fi) 2023-06-28

Family

ID=52822045

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16706413.8T FI3261679T3 (fi) 2015-02-23 2016-02-19 Geeniterapia näön parantamiseen

Country Status (29)

Country Link
US (3) US20180030477A1 (enExample)
EP (1) EP3261679B1 (enExample)
JP (1) JP6771474B2 (enExample)
KR (1) KR102272466B1 (enExample)
CN (1) CN107530449A (enExample)
AU (2) AU2016225277B2 (enExample)
CA (1) CA2977464C (enExample)
CY (1) CY1126098T1 (enExample)
DK (1) DK3261679T3 (enExample)
EA (1) EA201791900A1 (enExample)
ES (1) ES2947308T3 (enExample)
FI (1) FI3261679T3 (enExample)
GB (1) GB201503008D0 (enExample)
HK (1) HK1248594A1 (enExample)
HR (1) HRP20230775T1 (enExample)
HU (1) HUE062319T2 (enExample)
IL (1) IL254066B (enExample)
LT (1) LT3261679T (enExample)
MX (1) MX2017010772A (enExample)
MY (1) MY186444A (enExample)
PH (1) PH12017501525B1 (enExample)
PL (1) PL3261679T3 (enExample)
PT (1) PT3261679T (enExample)
RS (1) RS64372B1 (enExample)
SG (2) SG11201706822XA (enExample)
SI (1) SI3261679T1 (enExample)
SM (1) SMT202300200T1 (enExample)
WO (1) WO2016135457A1 (enExample)
ZA (1) ZA201706440B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3037436A1 (en) * 2016-09-22 2018-03-29 Sorbonne Universite Optogenetically transformed photoreceptor precursor cells for the use in the treatment of retinal degenerative diseases
WO2023280388A1 (en) * 2021-07-06 2023-01-12 Institute Of Molecular And Clinical Ophthalmology Basel Promoter for specific expression of genes in rod photoreceptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
CA2685900A1 (en) * 2006-05-04 2007-11-15 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
MX2010011467A (es) * 2008-04-18 2011-02-15 Novartis Forschungsstiftung Novedosas herramientas y metodos terapeuticos para tratar la ceguera.
GB2498325B (en) * 2010-10-15 2018-05-02 Eos Neuroscience Inc Engineered human GRM6 enhancer sequence for use in eye therapies
US8957028B2 (en) * 2010-11-13 2015-02-17 Massachusetts Institute Of Technology Red-shifted opsin molecules and uses thereof
WO2012167109A2 (en) * 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
WO2013124477A1 (en) * 2012-02-24 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
AU2015296502A1 (en) * 2014-07-29 2017-02-23 Circuit Therapeutics, Inc. System and method for optogenetic therapy

Also Published As

Publication number Publication date
JP2018506982A (ja) 2018-03-15
AU2016225277B2 (en) 2021-12-09
SMT202300200T1 (it) 2023-09-06
CY1126098T1 (el) 2023-11-15
US20250290096A1 (en) 2025-09-18
GB201503008D0 (en) 2015-04-08
SI3261679T1 (sl) 2023-09-29
MX2017010772A (es) 2018-03-01
CA2977464C (en) 2022-04-05
EA201791900A1 (ru) 2018-02-28
WO2016135457A1 (en) 2016-09-01
HUE062319T2 (hu) 2023-10-28
ZA201706440B (en) 2021-06-30
US20200377907A1 (en) 2020-12-03
BR112017018062A2 (pt) 2018-04-10
PH12017501525B1 (en) 2023-08-30
SG10202005923WA (en) 2020-07-29
KR102272466B1 (ko) 2021-07-02
IL254066A0 (en) 2017-10-31
AU2022201553A1 (en) 2022-03-31
HK1248594A1 (zh) 2018-10-19
AU2016225277A1 (en) 2017-10-12
RS64372B1 (sr) 2023-08-31
HRP20230775T1 (hr) 2023-10-27
US20180030477A1 (en) 2018-02-01
SG11201706822XA (en) 2017-09-28
LT3261679T (lt) 2023-07-10
JP6771474B2 (ja) 2020-10-21
IL254066B (en) 2021-10-31
PL3261679T3 (pl) 2023-09-04
DK3261679T3 (da) 2023-06-26
HK1248595A1 (en) 2018-10-19
EP3261679B1 (en) 2023-05-03
AU2022201553B2 (en) 2024-08-15
CN107530449A (zh) 2018-01-02
PT3261679T (pt) 2023-07-04
MY186444A (en) 2021-07-22
PH12017501525A1 (en) 2018-02-05
CA2977464A1 (en) 2016-09-01
ES2947308T3 (es) 2023-08-04
EP3261679A1 (en) 2018-01-03
NZ735735A (en) 2021-09-24
KR20180012737A (ko) 2018-02-06

Similar Documents

Publication Publication Date Title
JP2016535034A5 (enExample)
Hung et al. AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2020223362A8 (en) Compositions useful for treatment of pompe disease
JP2015523379A5 (enExample)
PH12018502387A1 (en) Adeno-associated virus variant capsids and methods of use thereof
WO2011133933A3 (en) Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
FI3546585T3 (fi) Muokatun intronin käsittäviä nukleiinihappoja käytettäviksi hyperbilirubinemian hoidossa
EA202191418A1 (ru) Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения
EA201990212A1 (ru) Композиции на основе системы crispr/cas9 и способы лечения дегенераций сетчатки
EP4219695A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
MX372992B (es) Vector de virus adeno-asociado.
HRP20201831T1 (hr) Optimizirani promoter rpe65 i kodirajuće sekvence
RU2020121390A (ru) SynP61, ПРОМОТОР, СПЕЦИФИЧЕСКИЙ В ОТНОШЕНИИ КЛЕТОК ПИГМЕНТНОГО ЭПИТЕЛИЯ СЕТЧАТКИ ПРИМАТОВ
RU2020121408A (ru) ПРОМОТОР SynPIII ДЛЯ СПЕЦИФИЧЕСКОЙ ЭКСПРЕССИИ ГЕНОВ В ПИГМЕНТНОМ ЭПИТЕЛИИ СЕТЧАТКИ
FI3261679T3 (fi) Geeniterapia näön parantamiseen
JOP20200253A1 (ar) تركيبات وطرق لعلاج الحثل البقعي
EA201991806A1 (ru) Опухоль-селективные мутанты tata-бокса и caat-бокса
KR20220030271A (ko) 헌팅턴병을 치료하기 위한 방법 및 재료
EP4364803A3 (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
WO2021066612A3 (ko) 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도
JP2018509154A5 (enExample)
MX2021007176A (es) Promotores híbridos y sus usos en terapia, especialmente para el tratamiento de colagenopatías tipo ii.
FI3737423T3 (fi) Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon
PH12017500998A1 (en) Treatment of ocular conditions using progenitor cells